ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IMTX / forecast
INBX (18) VOR (42) CGEM (32) ODTX (46) ⌘ Pro Terminal →

Immatics N.V. (IMTX) 12-Month Stock Forecast & Price Target Cone

$7.06 -1.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.02

Immatics N.V. (IMTX) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.08B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Immatics N.V. (NASDAQ: IMTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $7.06 (-1.94% 1D, market cap $1.08B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IMTX ranks #386 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMTX compare to INBX and VOR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMTX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, INBX (Inhibrx Biosciences Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.06B) and VOR (Vor Biopharma Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B). Among the 5-stock peer group, IMTX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMTX?
▼

For Immatics N.V. (IMTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #386 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.02 (-0.54%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D
Cash (12)Whales (3)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.2% Base Target
$13 Bull$7 Base$5 Bear
📬 FREE IMTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMTX)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY IMTX SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.8% FCF Margin ($30.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$6.83+10% Next Q
Q2 (-2Q)
39
Grade E$7.51-3.3% Next Q
Q3 (-1Q)
41
Grade D$7.26-2.8% Next Q
Current
44
Grade D$7.06-6.5% Hist 90D α
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMTX currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.19) and Max Pain ($7.41) forces dealer call-delta covering toward $13.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMTX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your IMTX Position Size: $10,000

Shares at $7.06: 1416.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $5.16
$7,309
$-2,691 (-26.9%)
12M Consensus BaseTarget $6.62
$9,377
$-623 (-6.2%)
12M Bull Case BreakoutTarget $13.03
$18,456
+$8,456 (+84.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$774%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1269%B
JP MorganUS Large-Cap ResearchSELL$658%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMTX)

  • ✓Walkthrough of IMTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IMTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.62%▼ DESCENDING CHANNEL
2026-11-03O $7.31H $7.31L $7.06C $7.06VOL 1.72M
RES: $8.43SUP: $6.13SMA50: $8.19SMA200: $9.56
$12.31$10.78$9.24$7.71$6.17RES $8.43SUP $6.13$7.062026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMTX Butterfly Map → + Track IMTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IMTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMTX)

Health Care Rank #386 of 1015 ⚔️ INBX vs IMTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMTX vs. INBX, VOR, CGEM, ODTX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Immatics N.V. (IMTX) ranks #386 by composite RQD confidence (44/100, grade D) and #348 by equity capitalization ($1.08B). Within this direct 5-issuer industry benchmark cohort, IMTX leads on earnings valuation at N/A trailing P/E, while INBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with IMTX at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IMTX ACTIVE
Immatics N.V.
D 44/100 — — — -1.94% $1.08B Benchmark Subject
INBX
Inhibrx Biosciences Inc.
E 18/100 — — -35.0% +0.53% $1.06B /inbx-vs-imtx →
VOR
Vor Biopharma Inc.
D- 42/100 — — -35.0% -2.18% $1.16B /vor-vs-imtx →
CGEM
Cullinan Therapeutics Inc.
E 32/100 — — -35.0% -0.66% $967.3M /cgem-vs-imtx →
ODTX
Odyssey Therapeutics Inc.
D 46/100 — — — -0.05% $939.1M /odtx-vs-imtx →

2. IMTX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Immatics N.V. (IMTX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $1.08B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IMTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Immatics N.V. (NASDAQ: IMTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $7.06 (-1.94% 1D, market cap $1.08B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IMTX ranks #386 in composite RQD confidence.

How does IMTX compare to INBX and VOR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMTX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, INBX (Inhibrx Biosciences Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.06B) and VOR (Vor Biopharma Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B). Among the 5-stock peer group, IMTX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMTX?

For Immatics N.V. (IMTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #386 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMTX trading relative to its 50-day, 200-day, and 52-week technical levels?

IMTX last traded at $7.06 (-1.94% on volume of 1,023,231 shares), positioning the stock -13.80% below its 50-day simple moving average ($8.19) and -26.15% below its 200-day simple moving average ($9.56). Across its 52-week range of $6.65 to $12.41, IMTX sits at the 7.1% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($6.23 to $7.89).

Direct Sub-Reports: IMTX RQD Cockpit IMTX 12M Forecast IMTX Earnings & Move IMTX Dividends & DRIP IMTX Insiders & 13F IMTX Whale Options IMTX Profit Sankey IMTX News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

IMTX — Immatics N.V.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Immatics N.V. (IMTX) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $7.06 (-1.94% 1D, market capitalization $1.08B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Immatics N.V. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry..1B. — describes its products, customers, or revenue model, so the specifics of how it makes money cannot be stated from the provided sources.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $6.65 – $12.41 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should recognize that the absence of mapped dependencies is itself a gap, not evidence of independence from sector trends.

  • Key Question #1: Can IMTX sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $12.41 52-week high?
  • Key Question #3: How sensitive is IMTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IMTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Immatics N.V. (IMTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IMTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IMTX Bull vs. Bear Conversation Board — What's Your Call at $7.06?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IMTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $9.29 (+29.0%)
📌 Pinned Debate

Forensic balance sheet pillar scores 13/20 with Altman Z of 2.5 and Piotroski F of 6/9, the strongest component of the rating.

The street is overcomplicating Immatics N.V. (IMTX). Forensic balance sheet pillar scores 13/20 with Altman Z of 2.5 and Piotroski F of 6/9, the strongest component of the rating.. With an RQD score of 44/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $7.78.

EarningsSniper 🐂 BULL

@CreditSpread_Watch Shorting a 3/20 institutional whale-flow stock at $7.20 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $5.40 (-25.0%)
Spot @ $7.20

Valuation & margin reality check on IMTX at $7.20 before chasing here

I respect the product at Immatics N.V., but the stock at $7.20 is a different story. Valuation & margin reality check on IMTX at $7.20 before chasing here. FCF yield is 0.0% and RQD sits at 44/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE